

## Study validates ThyroSeq V3 for diagnosis of cancer in thyroid nodules, 12/17

**December 2017**—ThyroSeq, a joint partnership between UPMC and CBLPath, announced the results of a double-blind, multicenter international study validating the performance of ThyroSeq V3 in thyroid nodules with indeterminate cytology. The results were presented at the 87th Annual Meeting of the American Thyroid Association, Oct. 18–22, in Victoria, British Columbia, Canada. A clinical oral presentation and a poster presentation demonstrated ThyroSeq’s V3 effective tools for a definitive diagnosis and ability to decrease the largest number of avoidable diagnostic surgeries.

“We are excited to have the opportunity to present our findings demonstrating the performance of this new, most comprehensive version of ThyroSeq for diagnosis of cancer in thyroid nodules,” Yuri Nikiforov, MD, PhD, professor of pathology, University of Pittsburgh Medical Center, and principal investigator of the multicenter ThyroSeq V3 trial, said in a statement. “The results of rigorous test validation in multiple clinical centers in the U.S. and abroad provide confidence that this most accurate test will allow us to save the largest number of avoidable thyroid surgeries and offer individualized management of patients with thyroid nodules and cancer based on the cutting-edge genomic science.”

[\*\*ThyroSeq\*\*](#), 877-225-7284